Grove Biopharma
Biotechnology company developing cell-penetrant, modular biologics for oncology and neurodegenerative diseases using proprietary platform technology from Northwestern University.
Notes
Grove Biopharma is developing cell-penetrant modular biologics for treating cancer and neurodegenerative diseases. The company's technology platform enables delivery of therapeutic proteins directly into cells, overcoming a major limitation of traditional biologic drugs that cannot cross cell membranes.
Founded as a spinout from Northwestern University, Grove Biopharma is developing therapeutics that can reach intracellular targets previously considered "undruggable" by conventional biologics.
The company is backed by Portal Innovations, a life science venture ecosystem based in Chicago that provides capital, facilities, and operational support to early-stage biotech companies.
Team
- Geoffrey Duyk, M.D., Ph.D. - CEO & Founder
- LinkedIn: linkedin.com/in/geoffreyduyk
- Experienced leadership team in drug development and biologics
Additional Research Findings
- Founded circa 2020 in Chicago
- University spinout: Northwestern University
- Portfolio company of Portal Innovations
- Pre-clinical stage company
- Cell-penetrant biologics platform
- Targets intracellular disease pathways
- Focus on oncology and neurodegeneration
- Leveraging novel protein delivery technology
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Portal Innovations | US | biotech-focused | - | 13 |